Valeant Pharma (VRX) Gains Early on Renewed Chatter

September 21, 2016 10:00 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Valeant Pharma (NYSE: VRX) is gaining early on reoccurring rumors the company has a bid for its Bausch & Lomb unit.

While originally saying it won't sell core assets like Bausch & Lomb, CEO Joe Papa recently softened his stance saying he'll 'never say never' on core assets sales.

Shares of VRX are up 1.25% early.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Add Your Comment